France's decision to double the medical co‑payment ceiling will raise out‑of‑pocket costs for patients, potentially increasing revenue for pharmaceutical firms and insurers while pressuring household budgets
Executive summary: The French government announced it will double the annual ceiling on medical co‑payments (franchises médicales), which has remained unchanged for 20 years, raising the limit from €50 to €100 per patient per year. Higher out‑of‑pocket costs affect household budgets, may increase demand for supplemental private insurance and over‑the‑counter medicines, and could boost revenues for pharmaceutical firms whose drugs are reimbursed under the new ceiling.
Who is involved: French Ministry of Health (Minister), patients, pharmaceutical companies, private health insurers, and the French social security system.
Likely next: The new ceiling takes effect immediately; its impact on drug utilization and public finances will be monitored, with a parliamentary review planned for September 2026 and possible adjustments based on inflation or public feedback.
The French government announced that the ceiling on medical franchises (the amount patients pay before insurance reimburses) will be doubled, ending a 20‑year freeze. The move aims to curb public health spending by shifting part of the cost to consumers. Analysts say higher patient contributions could boost sales of over‑the‑counter medicines and private insurance uptake, while raising concerns about affordability for low‑income households. The policy takes effect immediately and will be monitored for its impact on drug utilization and public finances.
Timeline
- — Médicaments, consultations : le gouvernement annonce le doublement du plafond des franchises médicales (Le Figaro — Économie)
- — Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy (PR Newswire)
Analysis — what this means
Likely next events
- Implementation of the doubled medical franchise ceiling takes effect immediately, July 23 2026.
- French Parliament to review the measure’s impact on social security finances in September 2026.
- Pharma companies expected to announce pricing adjustments for reimbursable drugs by Q4 2026.
- Patient advocacy groups planning a public demonstration against higher out‑of‑pocket costs by August 15 2026.
Sectors affected
- Pharmaceuticals
- Private health insurance
- Healthcare providers
- Consumer OTC medicines
Regulatory implications
- French Social Security budget for 2026‑2027 will be revised to reflect lower state reimbursement due to higher patient franchises.
- The French Haute Autorité de Santé will monitor changes in drug utilization and issue a report by March 2027.
- EU State Aid rules may be triggered if the measure is deemed to give undue advantage to private insurers.